oCI: Opto-electrical Cochlear Implants

Sponsor
Northwestern University (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05110183
Collaborator
Central DuPage Hospital (Other), University of Miami (Other), University of Missouri-Columbia (Other), National Institute on Deafness and Other Communication Disorders (NIDCD) (NIH)
30
3
1
56
10
0.2

Study Details

Study Description

Brief Summary

Neural stimulation with photons has been proposed for a next generation of cochlear implants (CIs). The potential benefit of photonic over electrical stimulation is its spatially selective activation of small populations of spiral ganglion neurons (SGNs). Stimulating smaller neuron populations along the cochlea provides a larger number of independent channels to encode acoustic information. Hearing could therefore be restored at a higher fidelity and performance in noisy listening environments as well as music appreciation are likely to improve .

While it has been demonstrated that optical radiation evokes auditory responses in animal models, it is not clear whether the radiant exposures used in the animal experiments are sufficient to stimulate the auditory system of humans. The proposed tests are:

  1. to demonstrate that light delivery systems (LDSs) can be inserted and oriented optimally in the human cochlea.

  2. to show that the LDSs are able to deliver sufficient amount of energy to evoke a compound action potential of the auditory nerve.

  3. to validate that the fluence rate (energy / target area) required for stimulation is below the maximal fluence rate, which damaged the cochlea in animal experiments.

  4. to show that combined optical and electrical stimulation is able to significantly lower the threshold required for optical stimulation in humans.

The endpoints for the study are either the completion of the experiments proposed or the demonstration that not sufficient energy can be delivered safely in the human cochlea to develop an action potential.

Condition or Disease Intervention/Treatment Phase
  • Device: electrical stimulation
  • Other: optical stimulation
  • Other: combined optical and electrical stimulation
N/A

Detailed Description

The patient is admitted to one of the participating clinical centers because of a brain tumor, which requires surgery to be removed. As discussed in detail with the treating surgeon, the tumor is large, and an approach will be used that accesses the tumor from the side through the temporal bone. This approach passes by the balance and hearing organ, and the partial or complete removal of the organ responsible for balance and hearing on this side is necessary. Participation in the study will extend the time of surgery by 30 minutes. There is no special preparation and no follow-up required for the study.

In this study, a cochlear implant system that uses light to stimulate the cochlea will be tested. It is a small light delivery system consisting of optical fibers and light sources the size of a human hair. This light delivery system will be inserted into the hearing organ, the cochlea before it is damaged or removed during the tumor surgery. After insertion into the cochlea, pulses of infrared light will be delivered to the cochlea, and auditory responses will be measured with a small electrode placed at the cochlea.

If possible, after completion of the measurements and during the continuation of the tumor surgery, the tissue of the hearing organ, which is typically destroyed through the drilling, will be harvested for histological evaluation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Device Feasibility
Official Title:
Opto-Electrical Cochlear Implants
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: electrical and optical hybrid stimulation stimulation

Patients with large tumors of the skull base, requiring a translabyrinthine craniotomy with sacrifice of their cochlea and vestibular system during the tumor resection may participate. A recording electrode will be placed on the round window, a cochleostomy will be created, and different Light delivery systems (LDSs) will be inserted into the cochlea. LDSs include angle polished optical fibers to determine the accuracy of the orientation of the radiation beam, and hybrid arrays of small optical sources and electrical contacts to evaluate electric-alone stimulation as a reference, and compare it to optic-alone and combined electrical and optical stimulation. Compound action potentials (CAPs) of the auditory nerve will be recorded.

Device: electrical stimulation
A cochlear implant electrode will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software on a laptop computer will be used to control the delivery of a sequence of charge balanced current pules.

Other: optical stimulation
Optical fibers will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Custom software will be used to control the delivery of a sequence of charge balanced current pules.

Other: combined optical and electrical stimulation
A short hybrid array consisting of optical sources and electrical contacts will be inserted through a cochleostomy into scala tympani of the cochlear basal turn. Biphasic electrical current pulse and optical pulse delivery will be controlled in amplitude and timing by a computer.

Outcome Measures

Primary Outcome Measures

  1. Compound Action Potential (CAP) [30 minutes]

    Compound action potentials (CAPs) of the auditory nerve in response to electrical stimulation, optical stimulation, and combined optical and electrical stimulation will be recorded. Electrical stimulation alone is used to determine baseline cochlear function. Optical stimulation alone will then be used to determine a similar baseline for optical stimulation and test parameters such as optical pulse rate, pulse duration and radiant exposure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Criterion for inclusion of a patient is the requirement of the translabyrinthine approach for tumor removal. The surgical approach is determined by the tumor size, the tumor location and the remaining hearing of the patient. Criteria for a translabyrinthine approach are:

  1. the tumor grows in the pontine angle and the facial nerve is at risk for damage during the surgery because the tumor is already large and in close proximity of the facial nerve AND

  2. the tumor is larger than 2.5 cm AND

  3. Pure tone hearing thresholds are elevated by at least 50 dB AND

  4. Speech discrimination scores are 50% or less

Exclusion Criteria:
  • adults unable to consent.

  • individuals who are not yet adults (infants, children, teenagers).

  • pregnant women.

  • prisoners.

  • vulnerable populations

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Miami Coral Gables Florida United States 33146
2 Central DuPage Hospital Association Winfield Illinois United States 60190
3 University of Missouri Columbia Missouri United States 65212

Sponsors and Collaborators

  • Northwestern University
  • Central DuPage Hospital
  • University of Miami
  • University of Missouri-Columbia
  • National Institute on Deafness and Other Communication Disorders (NIDCD)

Investigators

  • Principal Investigator: Claus-Peter Richter, MD, PhD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Claus-Peter Richter, Professor, Northwestern University
ClinicalTrials.gov Identifier:
NCT05110183
Other Study ID Numbers:
  • STU00209027
  • R01DC018666
First Posted:
Nov 5, 2021
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Claus-Peter Richter, Professor, Northwestern University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 18, 2022